MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 6 Sell Rating(s), 6 Hold Rating(s), 5 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Hold (Score: 2.06)
Consensus Price Target: $23.06 (3.87% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Leerink SwannReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Piper JaffrayReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016RBC CapitalReiterated RatingSector Perform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Robert W. BairdReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016OppenheimerReiterated RatingOutperform$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016WedbushReiterated RatingNeutral$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Jefferies GroupReiterated RatingSell$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016SunTrustDowngradeNeutral -> Reduce$14.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2016Needham & Company LLCReiterated RatingBuy$53.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016William BlairDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016JMP SecuritiesDowngradeMarket Perform -> Underperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Bank of AmericaInitiated CoverageBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Deutsche BankReiterated RatingHold$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/27/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha